Amgen and Ideaya Biosciences are winding down their cancer combination study, closing off one way the Big Biotech was looking to dial up the efficacy of its PRMT5 inhibitor AMG 193. The ...
Amgen's oncology portfolio continues to evolve, with AMG 193, a PRMT5 inhibitor for MTAP-null tumors, showing early promise. Phase I data revealed objective response rates of 18% for NSCLC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback